Q4 2025 Pharming Group NV Earnings Call Transcript
Key Points
- Pharming Group (PHGUF) reported a 27% increase in total revenues for the full year 2025, showcasing strong financial performance.
- The company achieved $26 million in operating profits in 2025, a significant turnaround from a loss in 2024.
- Pharming Group (PHGUF) increased its cash position, with operating cash flow reaching $55 million in 2025.
- The company's two commercial assets, Ruconest and Joenja, experienced substantial growth, with Joenja's revenue growing by 53% in Q4 2025.
- Pharming Group (PHGUF) has a promising late-stage pipeline with two programs offering billion-dollar sales potential, positioning the company for future growth.
- The company faces competitive dynamics in the HAE market, with new therapies entering the market and impacting Ruconest's growth.
- Pharming Group (PHGUF) received a complete response letter from the FDA regarding the pediatric label expansion for Joenja, indicating regulatory challenges.
- There is an expected inventory drawdown impacting Ruconest's revenue growth in Q1 2026, which could affect short-term financial performance.
- The company anticipates some pressure on growth early in 2026 due to market dynamics and competitive pressures.
- Pharming Group (PHGUF) is facing challenges in converting eligible patients to paid therapy, particularly in international markets where reimbursement processes are slower.
Good day and thank you for standing by. Welcome to the Farming Group NV 4th quarter and full year 2025 Financial Reserve Conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, please press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.
Please note that today's conference is being recorded. I would now like to turn the conference over to your first speaker, Mr. Fabrice Shirai, CEO. Please go ahead, sir.
Thank you, operator. Good morning and good afternoon everyone, and welcome to our Q4 and full year 2025 earning call.
I'll be joined on this call today by Leverne March, our new Chief Commercial Officer, Anurag Rahle, our Chief Medical Officer, and Kenneth Lynne, our Chief Financial Officer.
On this call, we will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
